Market Overview:
The global human chorionic gonadotropin (HCG) market size reached US$ 973.5 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,768.4 Million by 2032, exhibiting a growth rate (CAGR) of 6.65% during 2024-2032. The rising incidences of infertility in women, increasing prevalence of hypogonadism-related disorders, and production of HCG using recombinant technology represent some of the key factors driving the market.
Report Attribute
|
Key Statistics
|
Base Year
|
2023
|
Forecast Years
|
2024-2032
|
Historical Years
|
2018-2023
|
Market Size in 2023
|
US$ 973.5 Million |
Market Forecast in 2032
|
US$ 1768.4 Million |
Market Growth Rate 2024-2032 |
6.65% |
Human chorionic gonadotropin (HCG) is a chemical produced by syncytiotrophoblastic cells of the placenta during pregnancy. It is found in blood, urine, liver, colon, and pituitary glands. HCG stimulates the corpus luteum to produce progesterone to maintain the pregnancy. It is extracted and purified from the urine of pregnant women for clinical applications using various techniques, such as ion exchange chromatography, dye-affinity chromatography, nanofiltration, and reverse-phase high-performance liquid chromatography (HPLC). HCG is widely used to treat infertility, increase the chances of pregnancy, help in the production of testosterone and sperm, and treat cryptorchidism in male children. It also aids in diagnosing and monitoring pregnancy-related disorders, prenatal screening, and gynecological cancers.
Human Chorionic Gonadotropin (HCG) Market Trends:
The rising incidences of infertility among females due to uterine disorders, blocked fallopian tube, polycystic ovarian syndrome (PCOS), and endocrine system disorders are among the key factors driving the market growth. HCG is widely used in various assisted reproductive technologies, such as in-vitro fertilization (IVF) and intrauterine insemination (IUI), to treat female infertility, as it aids in inducing ovulation, promotes the formation of the embryo, facilitates correct timing of oocyte retrieval, increases endometrial thickness, and improve endometrial receptivity. In addition to this, the widespread product utilization in combination with other fertility drugs to increase the chances of pregnancy in women is acting as another growth-inducing factor. Furthermore, the increasing application of HCG to improve testosterone levels, enhance fertility, and promote sexual function due to the increasing prevalence of hypogonadism-related disorders in males suffering from obesity and type 2 diabetes is favoring the market growth. Additionally, the production of HCG using recombinant technology that provides identical properties, enhanced efficacy, and improved safety compared to naturally sourced HCG and enhances patient tolerance is positively influencing the market growth. Other factors, including the rapid development of healthcare infrastructure, increasing availability of treatment and services regarding infertility, rising geriatric population, extensive research and development (R&D) activities for the launch of novel purification and extraction technologies, and the implementation of various government initiatives to improve the sexual health of people, are anticipated to drive the market growth further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global human chorionic gonadotropin (HCG) market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on technology, therapeutic area, and end user.
Technology Insights:
- Natural Source Extraction
- Recombinant Technology
The report has also provided a detailed breakup and analysis of the human chorionic gonadotropin (HCG) market based on the technology. This includes natural source extraction and recombinant technology. According to the report, natural source extraction represented the largest segment.
Therapeutic Area Insights:
A detailed breakup and analysis of the human chorionic gonadotropin (HCG) market based on the therapeutic area has been provided in the report. This includes female infertility treatment, male hypogonadism, oligospermic treatment, and others. According to the report, female infertility treatment accounted for the largest market share.
End User Insights:
- Fertility Clinics
- Research Institutions
- Others
A detailed breakup and analysis of the human chorionic gonadotropin (HCG) market based on the end user has been provided in the report. This includes fertility clinics, research institutions, and others. According to the report, fertility clinics accounted for the largest market share.
Regional Insights:
- North America
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Latin America
- Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for human chorionic gonadotropin (HCG). Some of the factors driving the North America human chorionic gonadotropin (HCG) market include rising incidences of infertility among women, growing consumer awareness regarding the available treatment for infertility and gynecological concerns, and rising expenditure capacities of consumers.
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global human chorionic gonadotropin (HCG) market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Biocare Medical LLC, Ferring Pharmaceuticals, Fresenius SE & Co. KGaA, Kamiya Biomedical Company (Nitto Boseki Co. Ltd.), Lee Biosolutions Inc. (Oy Medix Biochemica Ab), Merck & Co. Inc., Prospec-Tany Technogene Ltd., Scripps Laboratories Inc., Sun Pharmaceutical Industries Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
US$ Million |
Technologies Covered |
Natural Source Extraction, Recombinant Technology |
Therapeutic Areas Covered |
Female Infertility Treatment, Male Hypogonadism, Oligospermic Treatment, Others |
End Users Covered |
Fertility Clinics, Research Institutions, Others |
Regions Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Biocare Medical LLC, Ferring Pharmaceuticals, Fresenius SE & Co. KGaA, Kamiya Biomedical Company (Nitto Boseki Co. Ltd.), Lee Biosolutions Inc. (Oy Medix Biochemica Ab), Merck & Co. Inc., Prospec-Tany Technogene Ltd., Scripps Laboratories Inc., Sun Pharmaceutical Industries Limited, etc. |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the global human chorionic gonadotropin (HCG) market performed so far and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global human chorionic gonadotropin (HCG) market?
- What are the key regional markets?
- Which countries represent the most attractive human chorionic gonadotropin (HCG) markets?
- What is the breakup of the market based on the technology?
- What is the breakup of the market based on the therapeutic area?
- What is the breakup of the market based on the end user?
- What is the competitive structure of the global human chorionic gonadotropin (HCG) market?
- Who are the key players/companies in the global human chorionic gonadotropin (HCG) market?
Key Benefits for Stakeholders:
- IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the human chorionic gonadotropin (HCG) market from 2018-2032.
- The research study provides the latest information on the market drivers, challenges, and opportunities in the global human chorionic gonadotropin (HCG) market.
- The study maps the leading as well as the fastest growing regional markets. It further enables stakeholders to identify the key country-level markets within each region.
- Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the human chorionic gonadotropin (HCG) industry and its attractiveness.
- Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.